与乙型肝炎患者乙型肝炎表面抗原丢失相关的细胞因子和趋

StephenW

JCI Insight. 2018 Oct 18;3(20). pii: 122268. doi: 10.1172/jci.insight.122268. [Epub ahead of print]
Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients.
Yoshio S1, Mano Y1, Doi H1, Shoji H1, Shimagaki T1, Sakamoto Y1, Kawai H1, Matsuda M1, Mori T1, Osawa Y1, Korenaga M1, Sugiyama M2, Mizokami M2, Mita E3, Katayama K4, Tanaka J4, Kanto T1.
Author information
Abstract
BACKGROUND:

The clearance of hepatitis B surface antigen (HBsAg) loss, defined as functional cure, is a clinical target in patients with chronic hepatitis B (CH). To understand the immune responses underlying functional cure, we evaluated cytokine and chemokine expression profiles from patients with resolving and nonresolving acute hepatitis B (AH).
METHODS:

We cross-sectionally evaluated 41 chemokines and cytokines at the peak of hepatitis in the sera from 41 self-limited AH patients who achieved HBsAg seroconversion, 8 AH patients who failed to clear HBsAg within 1 year after the diagnosis, 8 CH patients with hepatic flare, and 14 healthy volunteers. We longitudinally examined 41 chemokines and cytokines in the sera from 4 self-limited AH patients, 3 chimpanzees inoculated with hepatitis B virus (HBV), and 2 CH patients treated with nucleotide analogs and PEG-IFN-α, one resulting in functional cure.
RESULTS:

In AH patients and HBV-inoculated chimpanzees with HBsAg loss, CXCL9, CXCL10, CXCL11, CXCL13, and IL-21 were elevated at hepatitis with subsequent decline of HBsAg. Interestingly, IL-21 elevation was observed only in resolving AH patients but not in nonresolvers. CXCL13 and IL-21 elevation was not observed in CH patients who failed to attain HBsAg loss, even at hepatic flare. A concomitant increase of CXCL13 and IL-21 was significant in CH patients who attained HBsAg seroconversion with a sequential therapy.
CONCLUSION:

Elevation of serum CXCL9, CXCL10, CXCL11, CXCL13, and IL-21 might be a hallmark of functional cure of AH or CH patients.
KEYWORDS:

Chemokines; Cytokines; Hepatitis; Hepatology; Immunology

PMID:
    30333304
DOI:
    10.1172/jci.insight.122268

StephenW

JCI Insight。 2018年10月18日; 3（20）。 pii：122268。doi：10.1172 / jci.insight.122268。 [提前打印]
与乙型肝炎患者乙型肝炎表面抗原丢失相关的细胞因子和趋化因子特征。
Yoshio S1，Mano Y1，Doi H1，Shoji H1，Shimagaki T1，Sakamoto Y1，Kawai H1，Matsuda M1，Mori T1，Osawa Y1，Korenaga M1，Sugiyama M2，Mizokami M2，Mita E3，Katayama K4，Tanaka J4，Kanto T1 。
作者信息
抽象
背景：

乙型肝炎表面抗原（HBsAg）丢失的清除，定义为功能性治愈，是慢性乙型肝炎（CH）患者的临床目标。为了解功能性治愈的免疫反应，我们评估了解决和不治疗急性乙型肝炎（AH）患者的细胞因子和趋化因子表达谱。
方法：

我们对来自41名实现HBsAg血清转换的自限性AH患者，8名在诊断后1年内未能清除HBsAg的AH患者，8名患有肝脏疾病的CH患者的血清中的41位趋化因子和细胞因子进行了横断面评估。和14名健康志愿者。我们纵向检查了4名自限性AH患者血清中的41种趋化因子和细胞因子，3名接种乙型肝炎病毒（HBV）的黑猩猩和2名接受核苷酸类似物和PEG-IFN-α治疗的CH患者，其中一名患者进行了功能性治愈。
结果：

在AH患者和HBV接种的HBsAg缺失的黑猩猩中，CXCL9，CXCL10，CXCL11，CXCL13和IL-21在肝炎时升高，随后HBsAg下降。有趣的是，仅在解决AH患者时观察到IL-21升高，而在非溶栓患者中未观察到IL-21升高。即使在肝脏眩光下，未能达到HBsAg消失的CH患者也未观察到CXCL13和IL-21升高。在顺序疗法中获得HBsAg血清转换的CH患者中，CXCL13和IL-21的伴随增加是显着的。
结论：

血清CXCL9，CXCL10，CXCL11，CXCL13和IL-21的升高可能是AH或CH患者功能性治愈的标志。
关键词：

趋化因子;细胞因子;肝炎;肝病;免疫学

结论：
    30333304
DOI：
    10.1172 / jci.insight.122268